Sara R. Tanqueiro1,2†
Rita M. Ramalho1,2†Tiago M. Rodrigues1,2,3Luísa V. Lopes2Ana M. Sebastião1,2
Maria J. Diógenes1,2*- 1Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- 2Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal
- 3Department of Ophthalmology, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal
Brain-derived neurotrophic factor (BDNF) plays important functions in cell survival and differentiation, neuronal outgrowth and plasticity. In Alzheimer’s disease (AD), BDNF signaling is known to be impaired, partially because amyloid β (Aβ) induces truncation of BDNF main receptor, TrkB-full length (TrkB-FL). We have previously shown that such truncation is mediated by calpains, results in the formation of an intracellular domain (ICD) fragment and causes BDNF loss of function. Since calpains are Ca2+-dependent proteases, we hypothesized that excessive intracellular Ca2+ build-up could be due to dysfunctional N-methyl-d-aspartate receptors (NMDARs) activation. To experimentally address this hypothesis, we investigated whether TrkB-FL truncation by calpains and consequent BDNF loss of function could be prevented by NMDAR blockade. We herein demonstrate that a NMDAR antagonist, memantine, prevented excessive calpain activation and TrkB-FL truncation induced by Aβ25–35. When calpains were inhibited by calpastatin, BDNF was able to increase the dendritic spine density of neurons exposed to Aβ25135. Moreover, NMDAR inhibition by memantine also prevented Aβ-driven deleterious impact of BDNF loss of function on structural (spine density) and functional outcomes (synaptic potentiation). Collectively, these findings support NMDAR/Ca2+/calpains mechanistic involvement in Aβ-triggered BDNF signaling disruption.
Introduction
Brain-derived neurotrophic factor (BDNF) is a neurotrophin widely expressed in the central nervous system that, through activation of its full-length receptor (TrkB-FL), plays pivotal roles in cell survival and differentiation, axon elongation, dendritic growth and synaptic plasticity (Lewin and Barde, 1996; Lu et al., 2013). Truncated isoforms of TrkB receptors (TrkB-TC) act as negative modulators of TrkB-FL receptors (Eide et al., 1996; Dorsey et al., 2006), and changes in TrkB-FL:TrkB-TC ratio are thought to cause and/or reflect BDNF signaling dysfunction (Gomes et al., 2012). Cultured rat hippocampal or striatal neurons under excitotoxic conditions, such as exposure to glutamate, present a downregulation of TrkB-FL and upregulation of TrkB-TC receptors (Gomes et al., 2012), which may result in dysregulated actions of BDNF. Excitotoxicity and dysregulation of BDNF signaling are involved in several pathological processes, such as brain ischemia (Ferrer et al., 2001; Vidaurre et al., 2012; Tejeda et al., 2016), traumatic brain injury (Schober et al., 2012; Rostami et al., 2014) and neurodegenerative diseases (Porritt et al., 2005; Plotkin et al., 2014; Nguyen et al., 2016), including AD (Jerónimo-Santos et al., 2015). The link between excitotoxicity in AD and BDNF dysregulation is however not fully understood.
In AD, total BDNF levels are decreased and the TrkB-TC:TrkB-FL ratio is increased in hippocampal and cortical post-mortem samples from AD patients (Phillips et al., 1991; Connor et al., 1997; Allen et al., 1999; Ferrer et al., 1999; Holsinger et al., 2000). Such imbalance was suggested to contribute to cognitive impairment in AD (Morris, 1993). On the other hand, boosting BDNF/TrkB signaling was shown to ameliorate synaptic function and cognitive decline in mouse models of AD (Blurton-Jones et al., 2009; Nagahara et al., 2009; Devi and Ohno, 2012; Kemppainen et al., 2012).
We have previously demonstrated that Amyloid-β peptide (Aβ) – one of the main molecular drivers of the disease (Ittner and Götz, 2011) – is able to increase the expression of truncated isoforms of TrkB receptor in primary neuronal cultures (Kemppainen et al., 2012). Moreover, we showed that Aβ induces a calpain-dependent cleavage of TrkB-FL, which results in the formation of a previously unidentified truncated isoform (TrkB-T’) and of an ICD fragment (Jerónimo-Santos et al., 2015).
Calpains are intracellular Ca2+-dependent proteases that play physiological roles (Goll et al., 2003; Ono and Sorimachi, 2012). However, calpains were also reported to be dysregulated in aging-related diseases, such as AD (Nixon, 2003; Vosler et al., 2008), leading to excitotoxic neuronal death (Caba et al., 2002), synaptic dysfunction and spatial memory impairments (Trinchese et al., 2008; Granic et al., 2010; Medeiros et al., 2012). Excessive activation of calpains might result from increased intracellular Ca2+ concentrations that occur in excitotoxic conditions (Kelly and Ferreira, 2006, 2007). One source of intracellular Ca2+ are NMDARs, which have been implicated in excitotoxicity phenomena (Rueda et al., 2016). In animal models of AD, Aβ accumulation may lead to abnormal NMDAR activation, even in early stages (Parameshwaran et al., 2008). Moreover, Aβ was shown to induce a sustained Ca2+ influx by directly interacting with NMDARs, especially with those found at extrasynaptic sites (eNMDARs) (Alberdi et al., 2010; Texidó et al., 2011; Ferreira et al., 2012).
Thus, we hypothesized that eNMDARs could act as mediators of Aβ toxicity, by promoting Ca2+ influx and calpain activation, which would then lead to TrkB-FL truncation and BDNF signaling disruption. In order to experimentally address this hypothesis, we used the only NMDAR antagonist commercially available for the treatment of AD – memantine – as a pharmacological tool to preferentially block eNMDARs (Lipton, 2007; Parsons et al., 2007; Xia et al., 2010). Memantine, at doses that translate into plasmatic concentrations that are known to be highly selective to eNMDAR, has been shown to benefit cognitive function, a global outcome in patients with moderate to severe AD (Lipton, 2007; Parsons et al., 2007; Xia et al., 2010). Briefly, we herein show that memantine was able to reduce Aβ-induced TrkB-FL cleavage and to restore BDNF-mediated actions on spine density. In this regard, spine density was reported to be reduced in brain samples of both AD patients (Knobloch and Mansuy, 2008) and animal models (Spires et al., 2005; Spires-Jones et al., 2007), which has been related to the cognitive deficits. Importantly, BDNF is known to increase the number of dendritic spines (Tyler and Pozzo-Miller, 2001; Ji et al., 2005, 2010; Kellner et al., 2014), whereby promoting synaptic strength. Moreover, we show that memantine prevented Aβ-induced loss of BDNF effect on LTP, which is accepted as the synaptic correlate of learning and memory (Bliss and Collingridge, 1993). Collectively, our data support the thesis that NMDAR dysregulation may be mechanistically implicated in Aβ-induced BDNF signaling impairment.
Materials and Methods
Animals and Brain Areas Used
Sprague-Dawley and Wistar rats (Charles River, Barcelona, Spain) were maintained in controlled temperature (21 ± 1°C) and humidity (55 ± 10%) conditions with a 12:12 h light/dark cycle and access to food and water ad libitum. All animals were handled according to Portuguese Law and the European Union Directive (86/609/EEC) on the protection of animals for scientific experimentation. Care was taken to minimize the number of animals sacrificed.
Rats were deeply anesthetized with isoflurane (Esteve, Barcelona, Spain) and sacrificed for tissue preparation. The hippocampus was used for functional studies for two reasons: it is one of the brain areas more affected in AD and where BDNF effects have been most extensively studied (Figurov et al., 1996; Korte et al., 1998; Pang and Lu, 2004). On the other hand, since Aβ-induced dysregulation of TrkB receptors was reported to be similar in cortical and hippocampal cultures (Kemppainen et al., 2012), cortical cultures were used for molecular studies in order to increase culture yield and reduce the number of animals used.
Amyloid-β Peptides
All the experiments were performed using Aβ25–35 (Bachem, Bubendorf, Switzerland). As previously confirmed, Aβ25-35, which contains mainly protofibrillar and fibrillar amyloid structures (Del Mar Martínez-Senac et al., 1999; Kemppainen et al., 2012), represents the biologically active region of Aβ and induces the same molecular and cellular dysfunction as Aβ1–42, similar to what has been observed in AD brains (Pike et al., 1995; Kaminsky et al., 2010). Stock solutions of Aβ25–35 were prepared in MilliQ water to a final concentration of 1 mg/mL. We used 25 μM of Aβ25–35, as previously (Kemppainen et al., 2012; Jerónimo-Santos et al., 2015).
Primary Neuronal Cultures and Drug Treatments
Primary neuronal cultures were obtained from fetuses of 18/19-day pregnant Sprague-Dawley females. Unless stated otherwise, culture reagents and supplements were purchased from Gibco (Paisley, United Kingdom). The fetuses were collected in HBSS and, after brain dissection, the cerebral cortex was isolated, and the meninges were removed. The tissue was mechanically fragmented, and its digestion was performed with 0.025% (wt/vol) of trypsin solution in HBSS for 15 min at 37°C. After tissue digestion, cells were precipitated by centrifugation at 1200 rpm. The supernatant was removed and 20% of Fetal Bovine Serum was added to HBSS. Cells were again precipitated by centrifugation, the supernatant removed and 2 mL of HBSS was added to the solution. Cells resuspension by pipette aspiration was required between centrifugations in order to dissociate cells. This washing process was repeated four more times to neutralize trypsin. After washed, cells were resuspended in supplemented Neurobasal medium (0.5 mM L-glutamine, 25 mM glutamic acid, 2% B-27, and 25 U/mL penicillin/streptomycin). To obtain single cells and avoid cellular clusters or tissue fragments, the suspension was filtrated with a nylon filter (BD FalconTM Cell Strainer 70 μM, Thermo Fisher Scientific, Waltham, MA, United States). Cells were plated at densities of 6 × 104 and 5 × 104 cells/cm2 on coverslips for western blotting and immunocytochemistry experiments, respectively, and maintained at 37°C in a humidified atmosphere of 5% CO2. These coverslips were previously sterilized under UV light, coated overnight with 10 μg/mL of poly-D-lysine (Sigma-Aldrich, St. Louis, MO, United States) and then washed with sterile H2O. Primary neuronal cultures were incubated with 25 μM of Aβ25–35 at DIV13 for 24 h at 37°C, as previously described (Kemppainen et al., 2012; Jerónimo-Santos et al., 2015). In these experiments, cells were also co-incubated with Aβ25–35 and 1 μM memantine, a NMDAR antagonist (Sigma-Aldrich). Finally, for immunocytochemistry, cells were co-incubated with the same drugs and 1 μM of calpastatin (Millipore, Billerica, MA, United States), a cell-permeable calpain inhibitor, in the presence or absence of 20 ng/mL of BDNF, a gift from Regeneron Pharmaceuticals (Tarrytown, NY, United States). BDNF was used at a final concentration of 20 ng/mL (corresponding to ∼0.75 nM).
Western Blot (WB)
After treatments, primary neuronal cultures at DIV14 were washed with ice-cold PBS and lysed with Radio Immuno Precipitation Assay buffer (RIPA) [50 mM Tris–HCl (pH 7.5), 150 mM NaCl, 5 mM ethylenediaminetetraacetic acid, 0.1% SDS and 1% Triton X-100] containing protease inhibitors (Roche, Penzberg, Germany). Adherent cells were scraped off the dish using a cell scraper and the cell suspension were centrifuged at 13,000 g, 4°C during 10 min. The supernatant was aspired, discarding the pellet, and placed in fresh tubes. The amount of protein was determined by Bio-Rad DC reagent (Bio-Rad Laboratories, Berkeley, CA, United States) and all samples were prepared with the same amount of total protein (30 μg). A loading buffer (350 mM Tris pH = 6.8, 10% SDS, 30% glycerol, 600 mM Dithiothreitol, 0.06% bromophenol blue) was added and the mixture was boiled at 95–100°C for 5 min. Next, all samples and the molecular weight marker (Thermo Fisher Scientific) were loaded and separated on 10% SDS–polyacrylamide gel electrophoresis (SDS–PAGE) within a standard migration buffer (25 mM Tris pH = 8.3, 192 mM Glycine, 10% SDS), at a constant voltage between 80 and 120 mV. Then, proteins were transferred onto PVDF membranes (GE Healthcare, Buckinghamshire, United Kingdom), previously soaked in methanol for 5 min, within the standard buffer (25 mM Tris pH = 8.3, 192 mM Glycine, 15% methanol) for wet transfer conditions. After 1.5 h of transfer, membranes were soaked again in methanol for 5 min and then stained with Ponceau S solution to evaluate protein transference efficacy. Membranes were blocked with a 5% (w/v) non-fat dry milk solution in Tris-buffered saline with the detergent Tween-20 (20 mM Tris base, 137 mM NaCl and 0.1% Tween-20). Membranes were incubated overnight with primary antibodies: C-14 – the C-terminal of TrkB-FL rabbit polyclonal antibody (1:2000) and the αII-Spectrin (C-3) mouse monoclonal antibody (1:2500), raised against human spectrin (aa. 2368–2472) (Santa Cruz Biotechnology, Dallas, TX, United States) and 1 h at RT with goat anti-mouse and goat anti-rabbit IgG-horseradish peroxidase-conjugated secondary antibodies (Santa Cruz Biotechnology). Immunoreactivity was visualized using ECL chemiluminescence detection system (GE Healthcare), band intensity was measured using ChemiDoc (Bio-Rad Laboratories) and quantified by the digital densitometry ImageJ 1.45 software (Bethesda Softworks, Bethesda, MD, United States). The intensity of GAPDH was used as loading control.
Immunocytochemistry
Primary neuronal cultures at DIV14 were washed with PBS and then fixed in 4% paraformaldehyde in PBS (pH = 7.4) for 15 min at RT. Cells were incubated with the blocking solution (3% (w/v) bovine serum albumin) (Sigma-Aldrich) in PBS with 0.1% (v/v) Triton X-100 for 1 h. After new washes with PBS, cells were incubated with mouse microtubule-associated protein 2 (MAP2) primary antibody (1:200 in blocking solution) (Millipore), to specifically detect neurons, overnight at 4°C. After this, cells were washed with PBS and then incubated with Goat Anti-Mouse Alexa Fluor® 568 secondary antibody (1:200 in blocking solution) (Invitrogen), for 1 h at RT, in the dark. The secondary antibody solution was decanted and rinsed with PBS. Then, cells were incubated with Alexa Fluor® 488 Phalloidin (1:40 in PBS) (Invitrogen), which recognizes filamentous actin (F-actin), for 30 min. F-actin has an important role in the constitution of the cytoskeleton of dendritic spines (Koskinen and Hotulainen, 2014). After being washed, coverslips were mounted in Mowiol mounting solution and observed using an inverted fluorescent microscope Axiovert 135 TV (Carl Zeiss Microscopy, Thornwood, NY, United States). Spine density was counted as the number of protrusions per 10 μm of the parent dendrite, as previously reported (Alonso et al., 2004; Ji et al., 2010) with a distance of 25 μm from the cell body. We analyze 6 neurons per condition and, for each neuron, we counted protrusions in 3 different dendrites.
Freshly Prepared Hippocampal Slices
For electrophysiological studies, male Wistar rats (8–12 weeks old) were sacrificed after being deeply anesthetized with isoflurane. The brain was quickly removed and placed in ice-cold continuously oxygenated (O2/CO2: 95%/5%) aCSF (124 mM NaCl, 3 mM KCl, 1.2 mM NaH2PO4, 25 mM NaHCO3, 2 mM CaCl2, 1 mM MgSO4, and 10 mM glucose, pH 7,4) and the hippocampi were dissected free. The hippocampal slices were cut perpendicularly to the long axis of the hippocampus with a McIlwain tissue chopper (400 μm thick). After recovering functionally and energetically for at least 1 h in a resting chamber filled with oxygenated aCSF at RT, slices were incubated for 3 h either with aCSF (control), Aβ25–35 peptide (25 μM) alone, memantine (1 μM) alone or with both Aβ25–35 and memantine.
Ex Vivo Electrophysiology Recordings
Hippocampal slices were transferred to a recording chamber continuously superfused with oxygenated aCSF at 32°C (flow rate of 3 mL/min). fEPSPs were recorded extracellularly through a microelectrode filled with 4 M NaCl (2–6 MΩ) placed in the stratum radiatum of the CA1 area. Two different pathways of Schaffer collateral fibers were stimulated (rectangular pulses of 0.1 ms duration) at every 10 s by two bipolar concentric wire electrodes place on the Schaffer fibers. Recordings were obtained with an Axoclamp 2B amplifier (Axon Instruments, Foster City, CA, United States), digitized and continuously stored on a personal computer with the LTP software (Anderson and Collingridge, 2001). Individual responses were monitored and averages of six consecutive responses were obtained and the slope of the initial phase of the fEPSP was quantified. LTP induction and quantification were performed as described previously (Diogenes et al., 2011). Since the facilitatory action of BDNF upon LTP is mostly seen under weak 𝜃-burst protocol (three trains of 100 Hz, three stimuli, separated by 200) (Fontinha et al., 2008), LTP was induced by this protocol. Moreover, this pattern of stimulation is considered to be closer to what occurs in the hippocampus during episodes of learning and memory in living animals (Albensi et al., 2007). Therefore, we selected the more adequate stimulation paradigm to detect BDNF effect upon LTP (Fontinha et al., 2008), so that we could evaluate the modulatory influence of Aβ and memantine. After a stable fEPSP slope LTP was inducted in the first pathway. After 60 min of LTP induction, BDNF (20 ng/mL) was added to the superfusion solution. The intensity of stimulation was adjusted for similar values recorded before BDNF application. After at least 20 min of BDNF perfusion, LTP was induced in the second pathway. BDNF remained in the bath until the end of the experiment. LTP was quantified as % change in the average slope of the fEPSP taken from 46 to 60 min after LTP induction relatively to the average slope of the fEPSP measured during the 10 min before LTP induction. BDNF effect on LTP was evaluated by comparing the LTP magnitude in the first (control pathway, aCSF superfusion) and second pathway (test pathway, BDNF superfusion).
Statistical Analysis
Data are expressed as mean ± standard error of the mean (SEM) of the n number of independent experiments. Independent experiments are considered the results observed in different primary neuronal cultures obtained from fetuses of different pregnant-Sprague Dawley females and the results acquired from hippocampal slices of different Wistar rats.
For the analysis of the experiments reported in Figures 1, 2 and a two-way ANOVA model was used, considering two fixed factors (exposure to Aβ25–35 and memantine), each with two levels (presence versus absence). For the experiments in Figure 3, three-way ANOVA models were built, where three fixed factors (exposure to Aβ25–35, memantine/calpastatin and BDNF) were considered, each with two levels (presence versus absence). The mean squares, F-values and p-values of each source of variance within all ANOVA models built is provided as Supplementary Tables 1–7. Whenever a significant interaction was detected, a Tukey post hoc test was performed for multiple pairwise comparisons. For the experiments in Figure 4, paired t-tests were used to compare LTP magnitudes in the control and test pathways of the same slice.
FIGURE 1. The inhibition of eNMDAR reduces the cleavage of TrkB-FL by modulating calpains activation. (A) TrkB-FL protein levels. Representative western-blots of DIV14 neuronal cultures showing the effect of 24 h of 25 μM Aβ25–35 and 1 μM memantine on TrkB-FL (∼145 kDa). The panel shows the average band intensity of TrkB-FL (∗∗p < 0.01, n = 9–22, two-way ANOVA with Tukey post hoc test). (B) TrkB-ICD protein levels. Representative western-blots of DIV14 neuronal cultures showing the effect of 24 h of 25 μM Aβ25–35 and 1 μM memantine on TrkB-ICD (∼32 kDa). The panel shows the average band intensity of TrkB-ICD (∗∗p < 0.01, ∗∗∗p < 0.001, n = 10–20, two-way ANOVA with Tukey post hoc test) and (C) Calpains activation. Representative western-blots of DIV14 neuronal cultures showing the effect of 24 h of 25 μM Aβ25–35 and 1 μM memantine on SBDP (150 kDa). The panel shows the average ratio of the SBDP (150) to intact spectrin (∗∗p < 0.01, ∗∗∗p < 0.001, n = 7–20, two-way ANOVA with Tukey post hoc test). Results were normalized to the loading control, GAPDH. Values are mean ± SEM.
FIGURE 2. Neither Aβ nor memantine caused significant changes in different NMDAR subunits expression. (A) Representative western-blots of DIV14 neuronal cultures showing the effect of 24 h of 25 μM Aβ25–35 and 1 μM memantine on GluN1 and GluN2B. (B) The panels show the average band intensity of GluN1 (left histogram) and GluN2B (right histogram). Results were normalized to the loading control, GAPDH. Values are mean ± SEM.
FIGURE 3. Brain-derived neurotrophic factor (BDNF) restores its capacity to increase spine density after inhibition of Aβ-induced NMDAR activation. (A) Representative image of an untreated neuron obtained from primary cultures. DIV14 neurons were incubated with BDNF (20 ng/mL) for 24 h, in the presence or absence of Aβ25–35 (25 μM) and/or memantine (1 μM) or calpastatin (1 μM). MAP2 (red) specifically detects neurons, while phalloidin (green), recognizes F-actin, thus labeling protrusions (filopodia and spines). The merge of both elements is represented in yellow. Six neurons were analyzed per condition and spine density was considered, in each cell, as the number of protrusions per 10 μm of the parent dendrite with a distance of 25 μm from the cell body. Protrusions were counted in each neuron in three different dendrites. (B) Treatments effects on synaptic growth. Aβ significantly reduces the number of protrusions, whereas BDNF increases the number of protrusions when incubated alone. In the presence of Aβ, BDNF loses its ability to increase the number of protrusions, which is rescued when cells are incubated with memantine. (C) The panels show the average number of protrusions in different conditions when neurons were treated with memantine and (D) calpastatin (∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, n = 6–14, three-way ANOVA with Tukey post hoc test). Values are mean ± SEM.
FIGURE 4. The inhibition of NMDAR activation by Aβ restores the facilitatory effect of BDNF upon 𝜃-burst-induced LTP. (A,C,E) Panels in the left side show the averaged time courses changes in field excitatory post-synaptic potential (fEPSP) slope induced by a 𝜃-burst stimulation in the absence or in the presence of BDNF (20 ng/mL) in the second stimulation pathway in rat hippocampal slices without (A, n = 4) or with a pre-exposure for 3 h to aCSF solution containing 25 μM Aβ25–35 (C, n = 3) and 25 μM Aβ25–35 in the presence of 1 μM Mem (E, n = 7). Tracings from representative experiments are shown to the right of panels A,C,E; each tracing is the average of six consecutive responses obtained before (1 and 3) and 46–60 min after (2 and 4) LTP induction. Tracings are composed by the stimulus artifact, followed by the pre-synaptic volley and the fEPSP. Tracings 1 and 2 and tracings 3 and 4 were obtained in the absence and presence of BDNF, respectively. (B,D,F) Histograms depicting LTP magnitude (change in fEPSP slope at 46–60 min) induced by 𝜃-burst stimulation in the presence and absence of BDNF for each group of pretreated slices (control, Aβ25–35, Aβ25–35+Mem). (∗p < 0.05, n = 3–7, paired t-test) Values are mean ± SEM.
All statistics were performed on STATA (version 14.2, StataCorp LCC, College Station, TX, United States). P < 0.05 were considered statistically significant. Graphical representations were built on GraphPad (version 6.0f, La Jolla, CA, United States).
Results
The Inhibition of NMDAR Limits TrkB-FL Cleavage Induced by Aβ
Primary cultured cortical neurons were treated at DIV13 with Aβ25–35 fragment (25 μM) for 24 h, either in the presence or absence of memantine at a concentration (1 μM) highly selective to eNMDARs (Lipton, 2007; Parsons et al., 2007; Xia et al., 2010). Total proteins were then isolated, and TrkB-FL and TrkB-ICD levels were evaluated by WB.
Exposure to Aβ25–35 alone induced a marked decrease in TrkB-FL receptor levels (TrkB-FLAβ: 0.67 ± 0.06; TrkB-FLCTR: 1.00 ± 0.04, n = 10–22, p = 0.001, two-way ANOVA with Tukey post hoc test, Figure 1A and Supplementary Table 1) and a reciprocal increase in TrkB-ICD levels (TrkB-ICDAβ: 1.53 ± 0.10; TrkB-ICDCTR: 1 ± 0.07, n = 10–20, p < 0.001, two-way ANOVA with Tukey post hoc test, Figure 1B and Supplementary Table 2), as previously described (Jerónimo-Santos et al., 2015). Importantly, co-incubation with memantine (1 μM) prevented the Aβ-induced decrease of TrkB-FL receptors. Indeed, in these conditions, TrkB-FL increased (TrkB-FLAβ+Mem: 0.99 ± 0.07; TrkB-FLAβ: 0.67 ± 0.06, n = 9–10, p = 0.006, two-way ANOVA with Tukey post hoc test, Figure 1A) and TrkB-ICD decreased, relatively to exposure to Aβ25–35 alone (TrkB-ICDAβ+Mem: 1.02 ± 0.09; TrkB-ICDAβ: 1.53 ± 0.10, n = 10–11, p = 0.002, two-way ANOVA with Tukey post hoc test, Figure 1B), to levels similar to those of control conditions. Memantine alone had no significant effect on TrkB-FL (n = 9, p = 0.120, two-way ANOVA with Tukey post hoc test, Figure 1A) or TrkB-ICD expression levels (n = 12, p = 0.886, two-way ANOVA with Tukey post hoc test, Figure 1B).
Next, to evaluate if memantine could affect Aβ25–35-induced activation of calpains, αII-spectrin levels and the formation of calpain-specific spectrin breakdown products (SBDPs) were evaluated. αII-spectrin (250 kDa) is a major substrate for calpain and caspase-3 proteases, and its cleavage can produce breakdown products with distinct molecular weights. Specifically, calpains mediate the degradation of αII-spectrin to highly stable 150 kDa SBDPs (SBDP150). The presence of the calpain-cleaved fragments occurs early in neural cell pathology and may be indicative of necrotic and excitotoxic neuronal injury and death (Yan et al., 2012). Our data show that the exposure of neuronal cultures to Aβ25–35 resulted in high expression levels of SBDP150 (SBP150Aβ: 3.22 ± 0.40; SBP150CTR: 1.00 ± 0.24; n = 7–20, p < 0.001, two-way ANOVA with Tukey post hoc test, Figure 1C and Supplementary Table 3), strongly suggesting a marked activation of calpains as previously reported (Jerónimo-Santos et al., 2015). Importantly, memantine was able to prevent this effect, significantly reducing the levels of SBDP150 (SBP150Aβ+Mem:1.14 ± 0.37), when compared with Aβ25–35 alone (n = 7–8, p = 0.002, two-way ANOVA with Tukey post hoc test). Memantine (1 μM) alone had no significant effect upon calpain activity (n = 12–20, p = 0.994, two-way ANOVA with Tukey post hoc test Figure 1C).
N-methyl-d-aspartate receptors are tetramers of GluN1 and GluN2 subunits, with the latter being regarded as the subunit predominantly involved in excitotoxicity (Ferreira et al., 2012). To evaluate if the neuroprotective effects of memantine could correlate with changes in NMDAR subunit composition, we analyzed the levels of GluN2B and GluN1 subunits in primary neuronal cultured cells by WB. Interestingly, neither Aβ25–35 (25 μM) nor memantine (1 μM) significantly changed the expression levels of these subunits (Supplementary Tables 4, 5).
So far, our results suggest that, at least in our experimental conditions, memantine is able to prevent Aβ25–35-induced cleavage of TrkB-FL receptors, putatively by preferential blockade of eNMDAR (Xia et al., 2010) and through a mechanim independent of changes in NMDAR subunits expression levels.
NMDAR Inhibition Restores the Ability of BDNF to Increase Spine Density of Cultured Cortical Neurons
Next, we aimed to further clarify the structural and functional implications, at the synaptic level, of memantine ability to prevent Aβ25–35-induced impairment of BDNF signaling.
Firstly, we evaluated spine density of cultured cortical neurons as a morphological readout, since BDNF is known to positively modulate the number of dendritic spines (Tyler and Pozzo-Miller, 2001; Ji et al., 2005, 2010; Kellner et al., 2014).
Our data showed that exposure to BDNF (20 ng/mL) alone, for 24 h, significantly increased spine density, compared with control conditions (BDNF: 8.55 ± 0.28 vs. CTR: 7.34 ± 0.25, n = 11–14, p = 0.044, three-way ANOVA with Tukey post hoc test, Figure 3C and Supplementary Table 6). Conversely, the number of dendrites quantified in cultured neurons exposed to Aβ25–35 (25 μM) for 24 h was significantly reduced (Aβ: 5.21 ± 0.27 vs. CTR: 7.34 ± 0.25, n = 12–14, p < 0.001, three-way ANOVA with Tukey post hoc test, Figure 3C). Moreover, BDNF (20 ng/mL) lost its effect when Aβ25–35 (25 μM) was simultaneously present (BDNF+Aβ: 7.45 ± 0.29 vs. BDNF: 8.55 ± 0.28, n = 11, p = 0.135, three-way ANOVA with Tukey post hoc test, Figure 3C). However, this loss of effect was prevented in the presence of memantine (1 μM) (BDNF+ Aβ+MEM: 9.03 ± 0.36 vs. BDNF+Aβ: 7.45 ± 0.29, n = 7–11, p = 0.021, three-way ANOVA with Tukey post hoc test, Figure 3C). Memantine (1 μM) per se was able to prevent Aβ25–35-induced decrease in spine density (Aβ+MEM: 6.41 ± 0.33 vs. Aβ: 5.21 ± 0.27, n = 8–12, p = 0.037, three-way ANOVA with Tukey post hoc test, Figure 3C). Interestingly, memantine alone decreased spine density (MEM: 4.75 ± 0.39 vs. CTR: 7.34 ± 0.25, n = 6–14, p < 0.001, three-way ANOVA with Tukey post hoc test, Figure 3C). This can probably be explained by the fact that, in the absence of a neuronal insult, NMDAR activation might be required for neuronal homeostasis (Hunt and Castillo, 2012).
Next, we evaluated the contribution of calpains to the Aβ-mediated BDNF signaling impairment, on the same morphological readout. To this end, we used calpastatin (1 μM), a calpains inhibitor. Similarly to the results with memantine, calpastatin prevented both Aβ25–35-induced decrease in spine density (Aβ+CAL: 7.90 ± 0.30 vs. Aβ: 5.21 ± 0.27, n = 6–12, p < 0.001, three-way ANOVA with Tukey post hoc test, Figure 3D and Supplementary Table 7), as well as BDNF loss of effect in cultured neurons also exposed to Aβ25–35 (BDNF+Aβ+CAL: 9.43 ± 0.28 vs. BDNF+Aβ: 7.45 ± 0.29, n = 9–11, p < 0.001, three-way ANOVA with Tukey post hoc test, Figure 3D). Consistently, calpastatin alone did not significantly affect the number of dendritic protrusions (CAL: 7.25 ± 0.35 vs. CTR: 7.34 ± 0.25, n = 6–14, p = 1.000, three-way ANOVA with Tukey post hoc test, Figure 3D).
Altogether, these results suggest that both NMDAR blockade by memantine and calpain inhibition by calpastatin were able to restore BDNF effect on dendritic growth and to prevent Aβ25–35 deleterious effect on spine density. Since we have shown that NMDAR activation is upstream of calpain activation (Figure 1), we argue that the NMDAR/Ca2+/calpains pathway is mechanistically involved in mediating Aβ25–35-driven BDNF signaling impairment, as evaluated by exogenous BDNF effect on dendritic protrusions of cultured neurons.
The Inhibition of NMDAR Can Partially Rescue the Facilitatory Effect of BDNF Upon LTP
Given the possibility that NMDAR activation could be involved in TrkB-FL cleavage by calpains and consequently involved in BDNF loss of function, we next aimed to evaluate whether NMDAR blockade by memantine could also rescue the action of BDNF on LTP in hippocampal slices pre-exposed to Aβ (Jerónimo-Santos et al., 2015).
As previously shown (Fontinha et al., 2008), the 3×3 𝜃-burst paradigm delivered in the presence of BDNF (20 ng/mL) induced a robust LTP, which was significantly higher than that obtained in the absence of BDNF (LTPBDNF: 38.46 ± 10.46% vs. LTPCTR: 14.10 ± 3.50%, n = 4, p = 0.049 paired t-test, Figure 4B). However, when hippocampal slices were pretreated with Aβ25–35 (25 μM) for 3 h, BDNF (20 ng/mL) failed to significantly enhance LTP magnitude (LTPAβ: 17.68 ± 11.25% vs. LTPAβ+BDNF: 20.93 ± 7.95%, n = 3, p = 0.825, paired t-test, Figure 4D). When hippocampal slices were simultaneously pre-treated with Aβ25–35 (25 μM) and memantine (1 μM) for 3 h, the enhancement of LTP magnitude induced by BDNF was restored (LTPAβ+Mem+BDNF: 31.77 ± 8.59% vs. LTPAβ+Mem: 19.35 ± 4.14%, n = 7, p = 0.026, paired t-test, Figure 4F). Interestingly, although CA1 hippocampal 𝜃-burst LTP is known to be NMDAR-dependent (Citri and Malenka, 2008), pre-treatment with memantine did not significantly affect LTP, in experimental conditions similar to ours (Pinho et al., 2017).
Altogether, our data shows that memantine was able to rescue BDNF boosting effect upon LTP in slices exposed to Aβ25–35. Thus, our results strongly suggest that Aβ-mediated impairment of BDNF action relies, at least partially, on a NMDAR-depended mechanism, also for functional synaptic outcomes.
Discussion
Taken together, our results suggest that Aβ25–35 induces TrkB-FL cleavage through calpains that are activated, at least partially, by Ca2+ influx through NMDARs, which likely occurs at extrasynaptic sites, given the pharmacodynamic properties of memantine. TrkB-FL cleavage culminates in BDNF signaling disruption, as highlighted by BDNF loss of function on dendritic growth and synaptic potentiation. Conversely, when NMDARs were inhibited by memantine, loss of BDNF signaling was prevented, with beneficial structural and functional implications, at the synaptic level.
Brain-derived neurotrophic factor is a neurotrophin with key regulatory actions, on neuronal survival (Middleton et al., 2000), structural remodeling of excitatory spine synapses (Alonso et al., 2004), as well as in dendritic growth (Kumar et al., 2005) and plasticity (Arevalo and Wu, 2006). It acts through the activation of TrkB-FL receptors, which are coupled to three different signaling pathways: (i) the phosphatidylinositol-3-kinase (PI3K)/Akt pathway, (ii) the Ras/MAPK pathway, and (iii) the PLCγ pathway. Working together, these pathways underlie important cognitive processes, including memory formation. Apart from its full-length cognate receptor (TrkB-FL), BDNF can also bind to TrkB-TC, whereby a negative feedback on TrkB-FL signaling is activated (Eide et al., 1996; Dorsey et al., 2006). Consequently, many neuronal excitotoxic conditions are associated with downregulation of TrkB-FL and upregulation of TrkB-TC expression (Gomes et al., 2012). Moreover, BDNF levels were reported to be decreased in the CNS and in the blood of AD patients, which might indicate that BDNF is involved in the pathogenesis of this disease (Song et al., 2015). Furthermore, changes in BDNF signaling can lead to synaptic dysfunction that can account for memory deficits observed in AD (Arancio and Chao, 2007; Schindowski et al., 2008).
We have previously demonstrated that Aβ-induced impairment of BDNF actions on hippocampal LTP and neurotransmitter release were rescued when calpains were inhibited (Jerónimo-Santos et al., 2015). Given the central role of BDNF in synaptic physiology, a complete mechanistic understanding of its loss of function is of the utmost importance. Since calpains are overactivated by increased levels of Ca2+ (Kelly and Ferreira, 2006, 2007), we hypothesized that NMDARs could be implicated in the calpain-mediated cleavage of TrkB-FL. Indeed, NMDARs are an important homeostatic source of Ca2+ influx, but are also known to be involved in pathophysiological processes. Memantine – 1-amino-3,5-dimethyladamantane – is a commercially available drug currently used in clinical practice for the treatment of AD patients (Rogawski and Wenk, 2003; McShane et al., 2006; Parsons et al., 2007). It is an uncompetitive NMDA receptor antagonist with strong voltage dependency and rapid unblocking kinetics (Chen et al., 1992; Parsons et al., 1993). In addition, memantine has been used in several studies to selectively block the pathological activation of NMDARs, while leaving their physiological functions intact (Chen et al., 1992; Leveille et al., 2008; Papadia et al., 2008; Pinho et al., 2017). Thus, in the present study, we used memantine as a pharmacological tool to better understand NMDAR involvement in the mechanisms underlying TrkB-FL cleavage and its consequences.
Remarkably, we found that the cleavage of TrkB-FL in cortical cultured neurons treated with Aβ25–35 was prevented in the presence of memantine. This suggests that Aβ-induced NMDAR activation may contribute to the increased intracellular Ca2+ levels responsible for calpain activation and, subsequently, for TrkB-FL truncation. This is consistent with previous work showing that Aβ oligomeric species evoke an immediate rise in intracellular Ca2+ through activation of GluN2B subunit (Rönicke et al., 2011; Ferreira et al., 2012). NMDAR activation was shown to be upstream of calpain activation (del Cerro et al., 1994). Consistently, blockade of GluN2B prevented disruption of Ca2+ homeostasis induced by Aβ (Ferreira et al., 2012).
It is important to note, however, that distinct isoforms of calpains are differentially activated by synaptic and extrasynaptic NMDARs. In fact, synaptic NMDARs prefentially activate μ-calpains, while m-calpains are activated by eNMDAR (Parsons and Raymond, 2014). We did not evaluate the independent activation of different sets of calpains. However, it was previously shown that m-calpains induce the proteolysis of striatal-enriched protein phosphatase (STEP), activating the p38 mitogen-activated protein kinase (p38MAPK), wich culminates in cell death (Xu et al., 2009; Wang et al., 2013). Thus, we hypothesize that the overactivated calpains that are in the pathway culminating in TrkB cleavage are, most likely, of the m-subtype.
Brain-derived neurotrophic factor is known to facilitate or to boost hebbian plasticity mechanisms, which, in turn, rely on the formation of dendritic spines (Tartaglia et al., 2001; Knobloch and Mansuy, 2008). Therefore, we also evaluated whether NMDAR inhibition by memantine could prevent the Aβ25–35-induced BDNF loss of function upon spine density and synaptic potentiation. The results show that inhibition of NMDARs or calpains by memantine or calpastatin, respectively, was capable to restore BDNF effects on spine density in cultured cortical neurons, previously exposed to Aβ25–35, thus suggesting that NMDAR activation, probably upstream of calpain overactivation, contributes to Aβ-mediated BDNF loss of function upon spine density. This is consistent with previous results demonstrating that BDNF has important roles in spine outgrowth (Tyler and Pozzo-Miller, 2001; Ji et al., 2005, 2010; Kellner et al., 2014), which are impaired by Aβ (Shrestha et al., 2006; Smith D.L. et al., 2009). In addition, alterations in spine density are thought to contribute to cognitive deficits (Knobloch and Mansuy, 2008). Furthermore, it has been shown that NMDAR inhibition prevents the decrease in synaptic density in several animal models of AD (Shankar et al., 2007; Wei et al., 2010), which is in agreement with the data herein reported on cortical cultured neurons.
However, whether such NMDAR excessive activation is associated with changes in NMDAR subunits expression is not yet clear. Some evidence suggests that GluN1 mRNA levels are unchanged in AD patient’s brains (Bi and Sze, 2002), which is consistent with the results we obtained. On the other hand, it has been reported that expression of GluN2B mRNA and protein levels are decreased in the hippocampus and cortex of post-mortem human AD brain (Bi and Sze, 2002; Hynd et al., 2004; Mishizen-Eberz et al., 2004). It is possible that certain subunit combinations may be lost in AD because of selective neuronal loss. If so, retention of GluN1 transcripts suggests that neurons that express GluN2B NMDAR are comparatively more susceptible to neurotoxicity (Hynd et al., 2004). Other reports, however, showed that Aβ oligomers induced an increase of GluN2B membrane expression at extrasynaptic sites (Gilson et al., 2015). We did not observe significant changes in GluN2B protein levels in our experimental conditions. These discrepancies may be related with differences between AD models; namely, in our experimental setup, neurons were acutely exposed to Aβ25–35, which does not recapitulate the chronic and slow build-up of Aβ in the brains of AD patients. It may be that, in the early stages of AD before symptomatic onset, Aβ modulates the activity of NMDARs, putatively acting as a trigger to neurodegeneration. Furthermore, Aβ is known to enhance GluN2B-mediated NMDA currents and extrasynaptic responses. Thus, changes in NMDAR activity rather than changes in NMDAR composition may be early involved in the neurodegenerative cascade.
Long-term potentiation, widely accepted as the molecular substrate for learning and memory (Bliss and Collingridge, 1993), was used as a functional readout to evaluate the consequences of NMDAR inhibition. BDNF has the capacity to increase LTP magnitude through TrkB-FL activation (Korte et al., 1995; Figurov et al., 1996; Minichiello et al., 2002). Furthermore, LTP is correlated with the formation of new spines within minutes of induction (Toni et al., 1999; Lüscher and Malenka, 2012). We previously demonstrated that Aβ-induced impairments of BDNF actions upon hippocampal LTP are dependent on calpain activation (Jerónimo-Santos et al., 2015). The data herein presented expands our understanding of these processes, since NMDARs inhibition by memantine was also able to restore BDNF effect upon LTP. Hence, we hypothesize that, also for LTP, eNMDAR activation should be upstream of calpain overactivation leading to BDNF signaling impairment.
It is important to highlight that Aβ25–35 per se decreases spine density on primary neuronal cultures but has no significant effect upon LTP on hippocampal slices. Previous reports have shown that Aβ1–42, Aβ1–40 and the active fragment Aβ25–35 can significantly impair LTP in rat hippocampal slices (Chen et al., 2000). However, other reports have shown no significant changes on LTP magnitude (Smith J.P. et al., 2009; Jerónimo-Santos et al., 2015). The developmental age and genetic background of the animals used, the stimulation protocol or Aβ preparation (Smith J.P. et al., 2009) could explain such absence of Aβ effect upon LTP.
N-methyl-d-aspartate receptors, which are composed by four subunits (Paoletti et al., 2013), can be subdivided in synaptic and extrasynaptic subtypes (Hardingham et al., 2002), depending on their subcellular localization. NMDAR containing GluN2B are predominantly located extrasynaptically, while GluN2A-containing receptors have been mainly found at synaptic domains (Cull-Candy et al., 2001). The concentration of memantine used in this study, 1 μM, is within a concentration range that is known to target extrasynaptic receptors selectively (Xia et al., 2010). Therefore, we advance the hypothesis that NMDARs located at extrasynaptic sites are preferentially responsible for the rise in intracellular Ca2+ induced by Aβ, leading to TrkB-FL cleavage and the consequent BDNF loss of function. In line with this thesis, eNMDARs are known to be excessively activated in the presence of Aβ and in animal models of AD (Li et al., 2011; Talantova et al., 2013; Hanson et al., 2015). Consistently, inhibition of GluN2B-NMDARs was shown to prevent or reverse some of the synaptic deficits in animal models (Paoletti et al., 2013; Zhou and Sheng, 2013). If BDNF signaling disruption is prevented in the presence of memantine and given that BDNF is thought to play important neuroprotective effects, it is intriguing that the clinical benefit of memantine is only moderate, at best (Folch et al., 2017). The present work was not designed to answer this question. However, given that Aβ build-up is known to begin many years before symptomatic presentation, we argue that, at the time patients are commonly started on memantine, BDNF signaling will already be severely compromised, with little margin for such prophylactic effect (Caselli and Reiman, 2013).
In summary, our data revealed that inhibition of Aβ25–35-induced NMDAR activation by memantine: (i) prevents TrkB-FL truncation and (ii) prevents BDNF loss of effect on structural (spine density) and functional outcomes (LTP magnitude). Furthermore, we have shown that calpain activation is downstream of NMDARs and that calpain inhibition prevented Aβ25–35-induced BDNF loss of effect on dendritic protrusions. Thus, we propose that NMDAR activation, particularly at extrasynaptic sites, is mechanistically involved in Aβ-triggered intracellular Ca2+ build-up, consequently leading to calpain activation, TrkB-FL receptor cleavage and BDNF signaling impairment (Figure 5). By detailing the mechanisms involved in Aβ-induced cleavage of TrkB receptors and in the early functional consequences of this dysregulation, these findings highlight the role of eNMDAR activation upon BDNF signaling dysregulation in excitotoxic conditions leading to the neuronal dysfunction occurring in AD.
FIGURE 5. General overview of the main highlights of this work.
Ethics Statement
This study was carried out in accordance with the recommendations of “Directive 2010/63/EU.” The protocol was approved by the “iMM’s Institutional Animal Welfare Body – ORBEA-iMM and the National Competent Authority – DGAV (Direção-Geral de Alimentação e Veterinária).”
Author Contributions
ST and RR contributed equally to this work and were responsible for study concept and design, performed the experiments, interpreted the results, and wrote the initial draft of the manuscript. TR analyzed the data and revised the manusript. LL and AS contributed to interpretation of results and revised the manuscript. MD was responsible for the concept and design of the study, supervised the work, contributed to interpretation of the results and revised the manuscript.
Funding
RR was supported by Fundação para a Ciência e a Tecnologia (SFRH/BPD/94474/2013). ST was supported by Fundação para a Ciência e a Tecnologia (PD/BD/128091/2016). LL is an Investigator FCT. This work was supported by Santa Casa da Misericórdia (MB-37-2017) and SynaNet which has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement no. 692340. LISBOA-01-0145-FEDER-007391, project cofunded by FEDER, through POR Lisboa 2020 – Programa Operacional Regional de Lisboa, PORTUGAL 2020, and Fundao para a Ciência e a Tecnologia.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Acknowledgments
We thank Regeneron for the gift of Brain-derived neurotrophic factor.
Supplementary Material
The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2018.00237/full#supplementary-material
Abbreviations
Aβ, Amyloid-β peptide, aCSF, Artificial cerebrospinal fluid; AD, Alzheimer’s disease; BDNF, Brain-derived neurotrophic factor; eNMDAR, extrasynaptic N-methyl-d-aspartate receptor; fEPSPs, Field excitatory post-synaptic potential; HBSS, Hanks’ balanced salt solution; ICD, intracellular domain fragment; LTP, long-term potentiation; NMDAR, N-methyl-d-aspartate receptor; PBS, Phosphate-buffered saline; RT, Room temperature; SDS, Sodium dodecyl sulfate; SEM, Standard error of the mean; TrkB-FL, TrkB-full length; TrkB-T’, new truncated TrkB; TrkB-TC, truncated TrkB.
References
Albensi, B. C., Oliver, D. R., Toupin, J., and Odero, G. (2007). Electrical stimulation protocols for hippocampal synaptic plasticity and neuronal hyper-excitability: are they effective or relevant? Exp. Neurol. 204, 1–13. doi: 10.1016/j.expneurol.2006.12.009
Alberdi, E., Sánchez-Gómez, M. V., Cavaliere, F., Pérez-Samartín, A., Zugaza, J. L., Trullas, R., et al. (2010). Amyloid β oligomers induce Ca2+ dysregulation and neuronal death through activation of ionotropic glutamate receptors. Cell Calcium 47, 264–272. doi: 10.1016/j.ceca.2009.12.010
Allen, S. J., Wilcock, G. K., and Dawbarn, D. (1999). Profound and selective loss of 944 catalytic TrkB immunoreactivity in Alzheimer’s disease. Biochem. Biophys. Res. Commun. 264, 648–651. doi: 10.1006/bbrc.1999.1561
Alonso, M., Medina, J. H., and Pozzo-Miller, L. (2004). ERK1/2 activation is necessary for BDNF to increase dendritic spine density in hippocampal CA1 pyramidal neurons. Learn. Mem. 11, 172–178. doi: 10.1101/lm.67804
Anderson, W. W., and Collingridge, G. L. (2001). The LTP Program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J. Neurosci. Methods 108, 71–83. doi: 10.1016/S0165-0270(01)00374-0
Arancio, O., and Chao, M. V. (2007). Neurotrophins, synaptic plasticity and dementia. Curr. Opin. Neurobiol. 17, 325–330. doi: 10.1016/j.conb.2007.03.013
Arevalo, J. C., and Wu, S. H. (2006). Neurotrophin signaling: many exciting surprises! Cell Mol. Life Sci. 63, 1523–1537. doi: 10.1007/s00018-006-6010-1
Bi, H., and Sze, C. I. (2002). N-methyl-d-aspartate receptor subunit NR2A and NR2B messenger RNA levels are altered in the hippocampus and entorhinal cortex in Alzheimer’s disease. J. Neurol. Sci. 200, 11–18. doi: 10.1016/S0022-510X(02)00087-4
Bliss, T. V., and Collingridge, G. L. (1993). A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361, 31–39. doi: 10.1038/361031a0
Blurton-Jones, M., Kitazawa, M., Martinez-Coria, H., Castello, N. A., Müller, F.-J., Loring, J. F., et al. (2009). Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc. Natl. Acad. Sci. U.S.A. 106, 13594–13599. doi: 10.1073/pnas.0901402106
Caba, E., Brown, Q. B., Kawasaki, B., and Bahr, B. A. (2002). Peptidyl alpha-keto amide inhibitor of calpain blocks excitotoxic damage without affecting signal transduction events. J. Neurosci. Res. 67, 787–794. doi: 10.1002/jnr.10163
Caselli, R. J., and Reiman, E. M. (2013). Characterizing the preclinical stages of Alzheimer’s disease and the prospect of presymptomatic intervention. J. Alzheimers Dis. 33, S405–S416. doi: 10.3233/JAD-2012-129026
Chen, H. S., Pellegrini, J. W., Aggarwal, S. K., Lei, S. Z., Warach, S., Jensen, F. E., et al. (1992). Open-channel block of N-methyl-D-aspartate (n.d.) responses by memantine: therapeutic advantage against NMDA receptor mediated neurotoxicity. J. Neurosci. 12, 4427–4436.
Chen, Q. S., Kagan, B. L., Hirakura, Y., and Xie, C. W. (2000). Impairment of hippocampal long-term potentiation by Alzheimer amyloid beta-peptides. J. Neurosci. Res. 60, 65–72. doi: 10.1002/(SICI)1097-4547(20000401)60:1<65::AID-JNR7>3.0.CO;2-Q
Citri, A., and Malenka, R. C. (2008). Synaptic plasticity: multiple forms, functions, and mechanisms. Neuropsychopharmacology 33, 18–41. doi: 10.1038/sj.npp.1301559
Connor, B., Young, D., Yan, Q., Faull, R. L., Synek, B., and Dragunow, M. (1997). Brain-derived neurotrophic factor is reduced in Alzheimer’s disease. Brain Res. Mol. Brain Res. 49, 71–81. doi: 10.1016/S0169-328X(97)00125-3
Cull-Candy, S., Brickley, S., and Farrant, M. (2001). NMDA receptor subunits: diversity, development and disease. Curr. Opin. Neurobiol. 11, 327–335. doi: 10.1016/S0959-4388(00)00215-4
del Cerro, S., Arai, A., Kessler, M., Bahr, B. A., Vanderklish, P., Rivera, S., et al. (1994). Stimulation of NMDA receptors activates calpain in cultured hippocampal slices. Neurosci. Lett. 167, 149–152. doi: 10.1016/0304-3940(94)91049-9
Del Mar Martínez-Senac, M., Villalaín, J., and Gómez-Fernández, J. C. (1999). Structure of the Alzheimer β-amyloid peptide (25-35) and its interaction with negatively charged phospholipid vesicles. Eur. J. Biochem. 265, 744–753. doi: 10.1046/j.1432-1327.1999.00775.x
Devi, L., and Ohno, M. (2012). 7,8-dihydroxyflavone, a small-molecule TrkB agonist, reverses memory deficits and BACE1 elevation in a mouse model of Alzheimer’s disease. Neuropsychopharmacology 37, 434–444. doi: 10.1038/npp.2011.191
Diogenes, M. J., Costenla, A. R., Lopes, L. V., Jeronimo-Santos, A., Sousa, V. C., Fontinha, B. M., et al. (2011). Enhancement of LTP in aged rats is dependent on endogenous BDNF. Neuropsychopharmacology 36, 1823–1836. doi: 10.1038/npp.2011.64
Dorsey, S. G., Renn, C. L., Carim-Todd, L., Barrick, C. A., Bambrick, L., Krueger, B. K., et al. (2006). In vivo restoration of physiological levels of truncated TrkB.T1 receptor rescues neuronal cell death in a trisomic mouse model. Neuron 51, 21–28. doi: 10.1016/j.neuron.2006.06.009
Eide, F. F., Vining, E. R., Eide, B. L., Zang, K., Wang, X. Y., and Reichardt, L. F. (1996). Naturally occurring truncated trkB receptors have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J. Neurosci. 16, 3123–3129.
Ferreira, I. L., Bajouco, L. M., Mota, S. I., Auberson, Y. P., Oliveira, C. R., and Rego, A. C. (2012). Amyloid beta peptide 1-42 disturbs intracellular calcium homeostasis through activation of GluN2B-containing N-methyl-d-aspartate receptors in cortical cultures. Cell Calcium 51, 95–106. doi: 10.1016/j.ceca.2011.11.008
Ferrer, I., Krupinski, J., Goutan, E., Martí, E., Ambrosio, S., and Arenas, E. (2001). Brain-derived neurotrophic factor reduces cortical cell death by ischemia after middle cerebral artery occlusion in the rat. Acta Neuropathol. 101, 229–238.
Ferrer, I., Marin, C., Rey, M. J., Ribalta, T., Goutan, E., Blanco, R., et al. (1999). BDNF and full-length and truncated TrkB expression in Alzheimer disease. Implications in therapeutic strategies. J. Neuropathol. Exp. Neurol. 58, 729–739. doi: 10.1097/00005072-199907000-00007
Figurov, A., Pozzo-Miller, L. D., Olafsson, P., Wang, T., and Lu, B. (1996). Regulation of synaptic responses to high-frequency stimulation and LTP by neurotrophins in the hippocampus. Nature 381, 706–709. doi: 10.1038/381706a0
Folch, J., Busquets, O., Ettcheto, M., Sánchez-López, E., Castro-Torres, R. D., Verdaguer, E., et al. (2017). Memantine for the treatment of dementia: a review on its current and future applications. J. Alzheimers Dis. doi: 10.3233/JAD-170672 [Epub ahead of print].
Fontinha, B. M., Diogenes, M. J., Ribeiro, J. A., and Sebastiao, A. M. (2008). Enhancement of long-term potentiation by brain-derived neurotrophic factor requires adenosine A2A receptor activation by endogenous adenosine. Neuropharmacology 54, 924–933. doi: 10.1016/j.neuropharm.2008.01.011
Gilson, V., Mbebi-Liegeois, C., Sellal, F., and de Barry, J. (2015). Effects of low amyloid-β (Aβ) concentration on Aβ1-42 oligomers binding and GluN2B membrane expression. J. Alzheimers Dis. 47, 453–466. doi: 10.3233/JAD-142529
Goll, D. E., Thompson, V. F., Li, H., Wei, W., and Cong, J. (2003). The calpain system. Physiol. Rev. 83, 731–801. doi: 10.1152/physrev.00029.2002
Gomes, J. R., Costa, J. T., Melo, C. V., Felizzi, F., Monteiro, P., Pinto, M. J., et al. (2012). Excitotoxicity downregulates TrkB.FL signaling and upregulates the neuroprotective truncated TrkB receptors in cultured hippocampal and striatal neurons. J. Neurosci. 32, 4610–4622. doi: 10.1523/JNEUROSCI.0374-12.2012
Granic, I., Nyakas, C., Luiten, P. G., Eisel, U. L., Halmy, L. G., Gross, G., et al. (2010). Calpain inhibition prevents amyloid-beta-induced neurodegeneration and associated behavioral dysfunction in rats. Neuropharmacology 59, 334–342. doi: 10.1016/j.neuropharm.2010.07.013
Hanson, J. E., Pare, J., Deng, L., Smith, Y., and Zhoua, Q. (2015). Altered GluN2B NMDA receptor function and synaptic plasticity during early pathology in the PS2APP mouse model of Alzheimer’s disease. Neurobiol. Dis. 74, 254–262. doi: 10.1016/j.nbd.2014.11.017
Hardingham, G. E., Fukunaga, Y., and Bading, H. (2002). Extrasynaptic NMDARs oppose synaptic NMDARs by triggering CREB shut-off and cell death pathways. Nat. Neurosci. 5, 405–414. doi: 10.1038/nn835
Holsinger, R. M., Schnarr, J., Henry, P., Castelo, V. T., and Fahnestock, M. (2000). Quantitation of BDNF mRNA in human parietal cortex by competitive reverse transcription-polymerase chain reaction: decreased levels in Alzheimer’s disease. Brain Res. Mol. Brain Res. 76, 347–354. doi: 10.1016/S0169-328X(00)00023-1
Hunt, D. L., and Castillo, P. E. (2012). Synaptic plasticity of NMDA receptors: mechanisms and functional implications. Curr. Opin. Neurobiol. 22, 496–508. doi: 10.1016/j.conb.2012.01.007
Hynd, M. R., Scott, H. L., and Dodd, P. R. (2004). Differential expression of N-methyl-D-aspartate receptor NR2 isoforms in Alzheimer’s disease. J. Neurochem. 90, 913–919. doi: 10.1111/j.1471-4159.2004.02548.x
Ittner, L. M., and Götz, J. (2011). Amyloid-β and tau–a toxic pas de deux in Alzheimer’s disease. Nat. Rev. Neurosci. 12, 65–72. doi: 10.1038/nrn2967
Jerónimo-Santos, A., Vaz, S. H., Parreira, S., Rapaz-Lerias, S., Caetano, A. P., Buee-Scherrer, V., et al. (2015). Dysregulation of TrkB receptors and BDNF function by amyloid-beta peptide is mediated by calpain. Cereb. Cortex 25, 3107–3121. doi: 10.1093/cercor/bhu105
Ji, Y., Lu, Y., Yang, F., Shen, W., Tang, T. T., Feng, L., et al. (2010). Acute and gradual increases in BDNF concentration elicit distinct signaling and functions in neurons. Nat. Neurosci. 13, 302–309. doi: 10.1038/nn.2505
Ji, Y., Pang, P. T., Feng, L., and Lu, B. (2005). Cyclic AMP controls BDNF-induced TrkB phosphorylation and dendritic spine formation in mature hippocampal neurons. Nat. Neurosci. 8, 164–172. doi: 10.1038/nn1381
Kaminsky, Y. G., Marlatt, M. W., Smith, M. A., and Kosenko, E. A. (2010). Subcellular and metabolic examination of amyloid-beta peptides in Alzheimer disease pathogenesis: evidence for Abeta(25-35). Exp. Neurol. 221, 26–37. doi: 10.1016/j.expneurol.2009.09.005
Kellner, Y., Gödecke, N., Dierkes, T., Thieme, N., Zagrebelsky, M., and Korte, M. (2014). The BDNF effects on dendritic spines of mature hippocampal neurons depend on neuronal activity. Front. Synaptic Neurosci. 6:5. doi: 10.3389/fnsyn.2014.00005
Kelly, B. L., and Ferreira, A. (2006). beta-Amyloid-induced dynamin 1 degradation is mediated by N-methyl-D-aspartate receptors in hippocampal neurons. J. Biol. Chem. 281, 28079–28089. doi: 10.1074/jbc.M605081200
Kelly, B. L., and Ferreira, A. (2007). Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons. Neuroscience 147, 60–70. doi: 10.1016/j.neuroscience.2007.03.047
Kemppainen, S., Rantamaki, T., Jeronimo-Santos, A., Lavasseur, G., Autio, H., Karpova, N., et al. (2012). Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice. Neurobiol. Aging 33, 1122.e23–1122.e39. doi: 10.1016/j.neurobiolaging.2011.11.006
Knobloch, M., and Mansuy, I. M. (2008). Dendritic spine loss and synaptic alterations in Alzheimer’s disease. Mol. Neurobiol. 37, 73–82. doi: 10.1007/s12035-008-8018-z
Korte, M., Carroll, P., Wolf, E., Brem, G., Thoenen, H., and Bonhoeffer, T. (1995). Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. U.S.A. 92, 8856–8860. doi: 10.1073/pnas.92.19.8856
Korte, M., Kang, H., Bonhoeffer, T., and Schuman, E. (1998). A role for BDNF in the late-phase of hippocampal long-term potentiation. Neuropharmacology 37, 553–559. doi: 10.1016/S0028-3908(98)00035-5
Koskinen, M., and Hotulainen, P. (2014). Measuring F-actin properties in dendritic spines. Front. Neuroanat. 8:74. doi: 10.3389/fnana.2014.00074
Kumar, V., Zhang, M. X., Swank, M. W., Kunz, J., and Wu, G. Y. (2005). Regulation of dendritic morphogenesis by Ras-PI3K-Akt-mTOR and Ras-MAPK signaling pathways. J. Neurosci. 25, 11288–11299. doi: 10.1523/JNEUROSCI.2284-05.2005
Leveille, F., El Gaamouch, F., Gouix, E., Lecocq, M., Lobner, D., Nicole, O., et al. (2008). Neuronal viability is controlled by a functional relation between synaptic and extrasynaptic NMDA receptors. FASEB J. 22, 4258–4271. doi: 10.1096/fj.08-107268
Lewin, G. R., and Barde, Y. A. (1996). Physiology of the neurotrophins. Annu. Rev. Neurosci. 19, 289–317. doi: 10.1146/annurev.ne.19.030196.001445
Li, S., Jin, M., Koeglsperger, T., Shepardson, N. E., Shankar, G. M., and Selkoe, D. J. (2011). Soluble Abeta oligomers inhibit long-term potentiation through a mechanism involving excessive activation of extrasynaptic NR2B-containing NMDA receptors. J. Neurosci. 31, 6627–6638.
Lipton, S. A. (2007). Pathologically-activated therapeutics for neuroprotection: mechanism of NMDA receptor block by memantine and S-nitrosylation. Curr. Drug Targets 8, 621–632. doi: 10.2174/138945007780618472
Lu, B., Nagappan, G., Guan, X., and Nathan, P. J. (2013). BDNF-based synaptic repair as a disease-modifying strategy for neurodegenerative diseases. Nat. Rev. Neurosci. 14, 401–416. doi: 10.1038/nrn3505
Lüscher, C., and Malenka, R. C. (2012). NMDA receptor-dependent long-term potentiation and longterm depression (LTP/LTD). Cold Spring Harb. Perspect. Biol. 4:a005710. doi: 10.1101/cshperspect.a005710
McShane, R., Areosa Sastre, A., and Minakaran, N. (2006). Memantine for dementia. Cochrane Database. Syst. Rev. 19:CD003154. doi: 10.1002/14651858.CD003154.pub5
Medeiros, R., Kitazawa, M., Chabrier, M. A., Cheng, D., Baglietto-Vargas, D., Kling, A., et al. (2012). Calpain inhibitor A-705253 mitigates Alzheimer’s disease-like pathology and cognitive decline in aged 3xTgAD mice. Am. J. Pathol. 181, 616–625. doi: 10.1016/j.ajpath.2012.04.020
Middleton, G., Hamanoue, M., Enokido, Y., Wyatt, S., Pennica, D., Jaffray, E., et al. (2000). Cytokine-induced nuclear factor kappa B activation promotes the survival of developing neurons. J. Cell Biol. 148, 325–332. doi: 10.1083/jcb.148.2.325
Minichiello, L., Calella, A. M., Medina, D. L., Bonhoeffer, T., Klein, R., and Korte, M. (2002). Mechanism of TrkB-mediated hippocampal long-term potentiation. Neuron 36, 121–137. doi: 10.1016/S0896-6273(02)00942-X
Mishizen-Eberz, A. J., Rissman, R. A., Carter, T. L., Ikonomovic, M. D., Wolfe, B. B., and Armstrong, D. M. (2004). Biochemical and molecular studies of NMDA receptor subunits NR1/2A/2B in hippocampal subregions throughout progression of Alzheimer’s disease pathology. Neurobiol. Dis. 15, 80–92. doi: 10.1016/j.nbd.2003.09.016
Morris, J. C. (1993). The clinical dementia rating (CDR): current version and scoring rules. Neurology 43, 2412–2414. doi: 10.1212/WNL.43.11.2412-a
Nagahara, A. H., Merrill, D. A., Coppola, G., Tsukada, S., Schroeder, B. E., Shaked, G. M., et al. (2009). Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimer’s disease. Nat. Med. 15, 331–337. doi: 10.1038/nm.1912
Nguyen, K. Q., Rymar, V. V., and Sadikot, A. B. (2016). Impaired TrkB signaling underlies reduced BDNF-mediated trophic support of striatal neurons in the R6/2 mouse model of Huntington’s disease. Front. Cell Neurosci. 10:37. doi: 10.3389/fncel.2016.00037
Nixon, R. A. (2003). The calpains in aging and aging-related diseases. Ageing Res. Rev. 2, 407–418. doi: 10.1016/S1568-1637(03)00029-1
Ono, Y., and Sorimachi, H. (2012). Calpains: an elaborate proteolytic system. Biochim. Biophys. Acta 1824, 224–236. doi: 10.1016/j.bbapap.2011.08.005
Pang, P. T., and Lu, B. (2004). Regulation of late-phase LTP and long-term memory in normal and aging hippocampus: role of secreted proteins tPA and BDNF. Ageing Res. Rev. 3, 407–430. doi: 10.1016/j.arr.2004.07.002
Paoletti, P., Bellone, C., and Zhou, Q. (2013). NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat. Rev. Neurosci. 14, 383–400. doi: 10.1038/nrn3504
Papadia, S., Soriano, F. X., Leveille, F., Martel, M. A., Dakin, K. A., Hansen, H. H., et al. (2008). Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses. Nat. Neurosci. 11, 476–487. doi: 10.1038/nn2071
Parameshwaran, K., Dhanasekaran, M., and Suppiramaniam, V. (2008). Amyloid beta peptides and glutamatergic synaptic dysregulation. Exp. Neurol. 210, 7–13. doi: 10.1016/j.expneurol.2007.10.008
Parsons, C. G., Gruner, R., Rozental, J., Millar, J., and Lodge, D. (1993). Patch clamp studies on the kinetics and selectivity of N-methyl-D-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan). Neuropharmacology 32, 1337–1350. doi: 10.1016/0028-3908(93)90029-3
Parsons, M. P., and Raymond, L. A. (2014). Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 82, 279–293. doi: 10.1016/j.neuron.2014.03.030
Parsons, C. G., Stoffler, A., and Danysz, W. (2007). Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system–too little activation is bad, too much is even worse. Neuropharmacology 53, 699–723. doi: 10.1016/j.neuropharm.2007.07.013
Phillips, H. S., Hains, J. M., Armanini, M., Laramee, G. R., Johnson, S. A., and Winslow, J. W. (1991). BDNF mRNA is decreased in the hippocampus of individuals with Alzheimer’s disease. Neuron 7, 695–702. doi: 10.1016/0896-6273(91)90273-3
Pike, C. J., Walencewicz-Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., and Cotman, C. W. (1995). Structure-activity analyses of beta-amyloid peptides: contributions of the beta 25-35 region to aggregation and neurotoxicity. J. Neurochem. 64, 253–265. doi: 10.1046/j.1471-4159.1995.64010253.x
Pinho, J., Vale, R., Batalha, V. L., Costenla, A. R., Dias, R., Rombo, D., et al. (2017). Enhanced LTP in aged rats: detrimental or compensatory? J. Neuropharmacol. 114, 12–19. doi: 10.1016/j.neuropharm.2016.11.017
Plotkin, J. L., Day, M., Peterson, J. D., Xie, Z., Kress, G. J., Rafalovich, I., et al. (2014). Impaired TrkB receptor signaling underlies corticostriatal dysfunction in Huntington’s disease. Neuron 83, 178–188. doi: 10.1016/j.neuron.2014.05.032
Porritt, M. J., Batchelor, P. E., and Howells, D. W. (2005). Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons. Exp. Neurol. 192, 226–234. doi: 10.1016/j.expneurol.2004.11.030
Rogawski, M. A., and Wenk, G. L. (2003). The neuropharmacological basis for the use of memantine in the treatment of Alzheimer’s disease. CNS Drug Rev. 9, 275–308. doi: 10.1111/j.1527-3458.2003.tb00254.x
Rönicke, R., Mikhaylova, M., Rönicke, S., Meinhardt, J., Schröder, U. H., Fändrich, M., et al. (2011). Early neuronal dysfunction by amyloid β oligomers depends on activation of NR2B-containing NMDA receptors. Neurobiol. Aging 32, 2219–2228. doi: 10.1016/j.neurobiolaging.2010.01.011
Rostami, E., Krueger, F., Plantman, S., Davidsson, J., Agoston, D., Grafman, J., et al. (2014). Alteration in BDNF and its receptors, full-length and truncated TrkB and p75(NTR) following penetrating traumatic brain injury. Brain Res. 1542, 195–205. doi: 10.1016/j.brainres.2013.10.047
Rueda, C. B., Llorente-Folch, I., Traba, J., Amigo, I., Gonzalez-Sanchez, P., Contreras, L., et al. (2016). Glutamate excitotoxicity and Ca2+-regulation of respiration: role of the Ca2+ activated mitochondrial transporters (CaMCs). Biochim. Biophys. Acta 1857, 1158–1166. doi: 10.1016/j.bbabio.2016.04.003
Schindowski, K., Belarbi, K., and Buée, L. (2008). Neurotrophic factors in Alzheimer’s disease: role of axonal transport. Genes Brain Behav. 7, 43–56. doi: 10.1111/j.1601-183X.2007.00378.x
Schober, M. E., Block, B., Requena, D. F., Hale, M. A., and Lane, R. H. (2012). Developmental traumatic brain injury decreased brain derived neurotrophic factor expression late after injury. Metab. Brain Dis. 27, 167–173. doi: 10.1007/s11011-012-9309-7
Shankar, G. M., Bloodgood, B. L., Townsend, M., Walsh, D. M., Selkoe, D. J., and Sabatini, B. L. (2007). Natural Oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 27, 2866–2875. doi: 10.1523/JNEUROSCI.4970-06.2007
Shrestha, B. R., Vitolo, O. V., Joshi, P., Lordkipanidze, T., Shelanski, M., and Dunaevsky, A. (2006). Amyloid beta peptide adversely affects spine number and motility in hippocampal neurons. Mol. Cell. Neurosci. 33, 274–282. doi: 10.1016/j.mcn.2006.07.011
Smith, D. L., Pozueta, J., Gong, B., Arancio, O., and Shelanski, M. (2009). Reversal of long-term dendritic spine alterations in Alzheimer disease models. Proc. Natl. Acad. Sci. U.S.A. 106, 16877–16882. doi: 10.1073/pnas.0908706106
Smith, J. P., Lal, V., Bowser, D., Cappai, R., Masters, C. L., and Ciccotosto, G. D. (2009). Stimulus pattern dependence of the Alzheimer’s disease amyloid-beta 42 peptide’s inhibition of long term potentiation in mouse hippocampal slices. Brain Res. 1269, 176–184. doi: 10.1016/j.brainres.2009.03.007
Song, J. H., Yu, J. T., and Tan, L. (2015). Brain-derived neurotrophic factor in Alzheimer’s disease: risk, mechanisms, and therapy. Mol. Neurobiol. 52, 1477–1493. doi: 10.1007/s12035-014-8958-4
Spires-Jones, T. L., Meyer-Luehmann, M., Osetek, J. D., Jones, P. B., Stern, E. A., Bacskai, B. J., et al. (2007). Impaired spine stability underlies plaque-related spine loss in an Alzheimer’s disease mouse model. Am. J. Pathol. 171, 1304–1311. doi: 10.2353/ajpath.2007.070055
Spires, T. L., Meyer-Luehmann, M., Stern, E. A., Mclean, P. J., Skoch, J., Nguyen, P. T., et al. (2005). Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J. Neurosci. 25, 7278–7287. doi: 10.1523/JNEUROSCI.1879-05.2005
Talantova, M., Sanz-Blasco, S., Zhang, X., Xia, P., Akhtar, M. W., Okamoto, S., et al. (2013). Aβ induces astrocytic glutamate release, extrasynaptic NMDA receptor activation, and synaptic loss. Proc. Natl. Acad. Sci. U.S.A. 2, E2518–E2527. doi: 10.1073/pnas.1306832110
Tartaglia, N., Du, J., Tyler, W. J., Neale, E., Pozzo-miller, L., and Lu, B. (2001). Protein synthesisdependent and -independent regulation of hippocampal synapses by brain-derived neurotrophic factor. J. Biol. Chem. 276, 37585–37593. doi: 10.1074/jbc.M101683200
Tejeda, G. S., Ayuso-Dolado, S., Arbeteta, R., Esteban-Ortega, G. M., Vidaurre, O. G., and Díaz-Guerra, M. (2016). Brain ischaemia induces shedding of a BDNF-scavenger ectodomain from TrkB receptors by excitotoxicity activation of metalloproteinases and γ-secretases. J. Pathol. 238, 627–640. doi: 10.1002/path.4684
Texidó, L., Martin-Satué, M., Alberdi, E., Solsona, C., and Matute, C. (2011). Amyloid β peptide oligomers directly activate NMDA receptors. Cell Calcium 49, 184–190. doi: 10.1016/j.ceca.2011.02.001
Toni, N., Buchs, P. A., Nikonenko, I., Bron, C. R., and Muller, D. (1999). LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite. Nature 402, 421–425. doi: 10.1038/46574
Trinchese, F., Fa′, M., Liu, S., Zhang, H., Hidalgo, A., Schmidt, S. D., et al. (2008). Inhibition of calpains improves memory and synaptic transmission in a mouse model of Alzheimer disease. J. Clin. Invest. 118, 2796–2807. doi: 10.1172/JCI34254
Tyler, W. J., and Pozzo-Miller, L. D. (2001). BDNF enhances quantal neurotransmitter release and increases the number of docked vesicles at the active zones of hippocampal excitatory synapses. J. Neurosci. 21, 4249–4258.
Vidaurre, O. G., Gascón, S., Deogracias, R., Sobrado, M., Cuadrado, E., Montaner, J., et al. (2012). Imbalance of neurotrophin receptor isoforms TrkB-FL/TrkB-T1 induces neuronal death in excitotoxicity. Cell Death Dis. 3:e256. doi: 10.1038/cddis.2011.143
Vosler, P. S., Brennan, C. S., and Chen, J. (2008). Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration. Mol. Neurobiol. 38, 78–100. doi: 10.1007/s12035-008-8036-x
Wang, Y., Briz, V., Chishti, A., Bi, X., and Baudry, M., (2013). Distinct roles for μ-calpain and m-calpain in synaptic NMDAR-mediated neuroprotection and extrasynaptic NMDAR-mediated neurodegeneration. J. Neurosci. 33, 18880–18892. doi: 10.1523/JNEUROSCI.3293-13.2013
Wei, W., Nguyen, L. N., Kessels, H. W., Hagiwara, H., Sisodia, S., and Malinow, R. (2010). Amyloid beta from axons and dendrites reduces local spine number and plasticity. Nat. Neurosci. 13, 190–196. doi: 10.1038/nn.2476
Xia, P., Chen, H. S., Zhang, D., and Lipton, S. A. (2010). Memantine preferentially blocks extrasynaptic over synaptic NMDA receptor currents in hippocampal autapses. J. Neurosci. 30, 11246–11250. doi: 10.1523/JNEUROSCI.2488-10.2010
Xu, J., Kurup, P., Zhang, Y., Goebel-Goody, S. M., Wu, P. H., Hawasli, A. H., et al. (2009). Extrasynaptic NMDA receptors couple preferentially to excitotoxicity via calpain-mediated cleavage of STEP. J. Neurosci. 29, 9330–9343. doi: 10.1523/JNEUROSCI.2212-09.2009
Yan, X.-X., Jeromin, A., and Jeromin, A. (2012). Spectrin breakdown products (SBDPs) as potential biomarkers for neurodegenerative diseases. Curr. Transl. Geriatr. Exp. Gerontol. Rep. 1, 85–93. doi: 10.1007/s13670-012-0009-2
Keywords: Alzheimer’s disease, brain-derived neurotrophic factor, TrkB receptor, extrasynaptic N-methyl-d-aspartate receptors, memantine, long-term potentiation, spine density, synaptic plasticity
Citation: Tanqueiro SR, Ramalho RM, Rodrigues TM, Lopes LV, Sebastião AM and Diógenes MJ (2018) Inhibition of NMDA Receptors Prevents the Loss of BDNF Function Induced by Amyloid β. Front. Pharmacol. 9:237. doi: 10.3389/fphar.2018.00237
Received: 26 September 2017; Accepted: 02 March 2018;
Published: 11 April 2018.
Edited by:
Ashok Kumar, University of Florida, United StatesReviewed by:
Kathy R. Magnusson, Oregon State University, United StatesMarina Mikhaylova, Universitätsklinikum Hamburg-Eppendorf, Germany
Copyright © 2018 Tanqueiro, Ramalho, Rodrigues, Lopes, Sebastião and Diógenes. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Maria J. Diógenes, ZGlvZ2VuZXNAbWVkaWNpbmEudWxpc2JvYS5wdA==
†Co-first authors